Arcus Biosciences, Inc.
PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS

Last updated:

Abstract:

Methods of identifying compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and that possess particular pharmacokinetic characteristics are described herein. Methods of such compounds, and compositions comprising same, for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, are also provided.

Status:
Application
Type:

Utility

Filling date:

8 Mar 2019

Issue date:

31 Dec 2020